BIOMAT Database Logo BIOMAT Database Logo

Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab. 2004

Andrew J K Ostor, and Adrian J Crisp, and Margaret F Somerville, and David G I Scott
Department of Rheumatology, Addenbrooke's Hospital, Cambridge CB2 2QQ. andrew.ostor@addenbrookes.nhs.uk

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011658 Pulmonary Fibrosis A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death. Alveolitis, Fibrosing,Idiopathic Diffuse Interstitial Pulmonary Fibrosis,Fibroses, Pulmonary,Fibrosis, Pulmonary,Pulmonary Fibroses,Alveolitides, Fibrosing,Fibrosing Alveolitides,Fibrosing Alveolitis
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069285 Infliximab A chimeric monoclonal antibody to TNF-ALPHA that is used in the treatment of RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; PSORIATIC ARTHRITIS and CROHN'S DISEASE. Inflectra,Infliximab-abda,Infliximab-dyyb,MAb cA2,Monoclonal Antibody cA2,Remicade,Renflexis,Antibody cA2, Monoclonal,Infliximab abda,Infliximab dyyb,cA2, Monoclonal Antibody
D000075202 Contraindications A condition or factor associated with a recipient that makes the use of a drug, procedure, or physical agent improper or inadvisable. Contraindications may be absolute (life threatening) or relative (higher risk of complications in which benefits may outweigh risks). Contraindications, Physical Agent,Medical Contraindications,Agent Contraindication, Physical,Agent Contraindications, Physical,Contraindication,Contraindication, Medical,Contraindication, Physical Agent,Contraindications, Medical,Medical Contraindication,Physical Agent Contraindication,Physical Agent Contraindications
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis

Related Publications

Andrew J K Ostor, and Adrian J Crisp, and Margaret F Somerville, and David G I Scott
[Fibrosing alveolitis after treatement of rheumatoid arthritis by infliximab].
October 2009, Presse medicale (Paris, France : 1983),
Andrew J K Ostor, and Adrian J Crisp, and Margaret F Somerville, and David G I Scott
Fibrosing alveolitis in rheumatoid arthritis.
October 1967, The Indian journal of chest diseases,
Andrew J K Ostor, and Adrian J Crisp, and Margaret F Somerville, and David G I Scott
Survival in fibrosing alveolitis associated with rheumatoid arthritis is better than cryptogenic fibrosing alveolitis.
April 2003, Rheumatology (Oxford, England),
Andrew J K Ostor, and Adrian J Crisp, and Margaret F Somerville, and David G I Scott
Tc-DTPA clearance and rheumatoid arthritis-associated fibrosing alveolitis.
June 2002, Rheumatology (Oxford, England),
Andrew J K Ostor, and Adrian J Crisp, and Margaret F Somerville, and David G I Scott
Familial association of rheumatoid arthritis and fibrosing alveolitis.
May 1974, Annals of the rheumatic diseases,
Andrew J K Ostor, and Adrian J Crisp, and Margaret F Somerville, and David G I Scott
Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab.
June 2006, Annals of the rheumatic diseases,
Andrew J K Ostor, and Adrian J Crisp, and Margaret F Somerville, and David G I Scott
Predictors of progression of HRCT diagnosed fibrosing alveolitis in patients with rheumatoid arthritis.
June 2002, Annals of the rheumatic diseases,
Andrew J K Ostor, and Adrian J Crisp, and Margaret F Somerville, and David G I Scott
Dothiepin and fatal fibrosing alveolitis.
April 1986, Lancet (London, England),
Andrew J K Ostor, and Adrian J Crisp, and Margaret F Somerville, and David G I Scott
Fatal fibrosing alveolitis with certolizumab.
May 2012, Rheumatology (Oxford, England),
Andrew J K Ostor, and Adrian J Crisp, and Margaret F Somerville, and David G I Scott
[2 cases of fibrosing alveolitis in patients with rheumatoid arthritis treated with chrysanol].
September 1990, Klinicheskaia meditsina,
Copied contents to your clipboard!